Drug Safety Label Changes: A Target for Collaboration

“Communicating the most up-to-date information on a product’s safety to patients and providers is one of FDA’s most important functions,” said Mark McClellan, MD, PhD, director of Duke Margolis Center for Health Policy.

Collaboration is needed to help the FDA increase its understanding of the impact of postmarketing drug safety. Read the full press release here.